Tempus’ mission is to apply data and AI to diagnostics in order to route every patient to a personalized, optimal therapeutic path. We’re helping treat the patients of today while finding cures for the patients of tomorrow. We are pleased to share our latest scientific and clinical research findings during the 2022 ASCO® Annual Meeting (Booth #5063).
Join us for lab tours, interactive demos, conversation, food, and drinks on Sunday, June 5, 2022 @ 6 – 8 pm CDT
Tempus
600 West Chicago Avenue Chicago, IL 60654. Transportation from McCormick Place provided. Please contact events@tempus.com with any questions.
Live Session: 6/6/2022 @ 9:30 am – 10:30 am CDT
Presenter: Sibel Blau (Northwestern Medical)
Live Session: 6/6/2022 @ 3:00 pm – 6:00 pm CDT
By combining TIME trial and traditional enrollment models clinical trials may recruit more patients and reach full enrollment faster
Read morePresenter: Wade Iams; Vanderbilt
Live Session: 6/5/2022 @ 8:00 am – 11:00 am CDT & 4:30 pm – 6:00 pm CDT
Performing liquid biopsy in addition to tissue based testing identifies more patients with clinically actionable variants
Read moreLead Author: Jack Michuda; Tempus Labs
Live Session: 6/6/2022 @ 3:00 pm to 6:00 pm CDT
In the largest fusion analysis of its kind Tempus reviewed a real-world data set of 77,400 patient records for improvement in clinically actionable fusion detection due to the inclusion of RNA sequencing; The inclusion of RNA sequencing improves fusion detection vs DNA alone
Read morePresenter: Robin Buerki; Northwestern
Live Session: 6/5/2022 @ 8:00 am – 11:00 am CDT & 11:30 am – 1:00 pm CDT
Researchers analyzed a de-identified dataset of CNS tumors and found that reclassifying according to the new WHO classification system resulted in more accurate prognostic stratification than the original diagnosis
Read moreFirst Author: Nina Sanford; UTSW
6/4/2022 @ 8:00 am – 11:00 am CDT
Used genetic ancestry instead of race/ethnicity classes to provide a more quantitative and precise profile of shared genetic background that can underlie biological race differences in cancer etiology and outcomes
Read moreFirst Author: Christopher W. Seder; Rush University
6/5/2022 @ 8:00 am – 11:00 am CDT
The use of xT tumor/normal match reduced apparent discrepancy in TMB levels between racial groups, particularly for Black and Asian patients
Read moreTodd Knepper; Moffitt, Prateek Gulhati; Rutgers
6/4/2022 @ 8:00 am – 11:00 am CDT
Read moreJacob Koskimaki; Astrazeneca
6/4/2022 @ 1:15 pm – 4:15 pm CDT
Read moreMohamed E. Salem; Levine Cancer Institute
6/5/2022 @ 8:00 am – 11:00 am CDT
Read moreBrian Pham; UC Davis
6/5/2022 @ 8:00 am – 11:00 am CDT
Read moreMohamed E. Salem; Levine Cancer Institute
6/5/2022 @ 8:00 am – 11:00 am CDT
Read moreSukhmani Kaur Padda; Cedars Sinai
6/5/2022 @ 8:00 am – 11:00 am CDT
Read more